AKBA - Akebia Ther logo

Akebia Ther

AKBA

Akebia Therapeutics develops and commercializes therapies for kidney diseases, offering Vafseo for anemia in chronic kidney disease and Auryxia for controlling serum phosphorus. It also has clinical trials focused on cardiac surgery-related kidney injury and retinopathy.

⚕️ Healthcare NASDAQ Listed 2014 $ USD
$1,000 invested 10 years ago →$69today

Score Overview

1 Year
Score
Net Growth-455.02%
Net TrendShrank
Net Income Consistency—
Rev Growth-7.26%
Rev TrendShrank
Revenue Consistency—
5 Years
Score5.2
Net Growth87.89%
Net Trend60%
Net Income Consistency—
Rev Growth2.57%
Rev Trend40%
Revenue Consistency—
10 Years
Score—
Net Growth78.15%
Net Trend50%
Net Income Consistency
Rev Growth—
Rev Trend44%
Revenue Consistency
All Time
Score
Net Growth19.90%
Net Trend42%
Net Income Consistency
Rev Growth312x
Rev Trend40%
Revenue Consistency

Explore the 2021 public Archive ranking →

Where Akebia Ther has ranked, year by year

Measure
Fundamentals Window

Not enough ranking history to display a chart

This chart needs at least two years of available HDB Score rankings on 10 years of fundamentals. AKBA does not have enough ranked years in the public Archive through 2021.

More recent Archive years are available with Membership. Coverage varies by company and measure.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-10-22
$ 0.56—
1 Year2025-10-22
$ 2.99-81.20%
5 Years2021-10-22
$ 2.91-80.68%
10 Years2016-10-21
$ 8.09-93.05%
All Time2014-03-20
$ 26.70-97.89%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in USD

Year
TTM$ 219M-$ 29M$ 155M
2025$ 236M-$ 5M$ 184M
2024$ 160M-$ 69M$ 51M
2023$ 194M-$ 51M$ 42M
2022$ 292M-$ 94M$ 90M
2021$ 213M-$ 244M$ 149M
2020$ 295M-$ 349M$ 269M
2019$ 335M-$ 279M$ 147M
2018$ 207M-$ 171M$ 321M
2017$ 177M-$ 76M$ 317M
2016-$ 135M$ 260M
2015$ 0.00-$ 60M$ 138M
IPO2014$ 700.23K-$ 37M$ 108M
AKBA - Akebia Ther logo

Akebia Ther fundamental performance

Between 2020 and 2025, revenue declined from $ 295M to $ 236M and net income went from -$ 349M to -$ 5M. Revenue increased in 2 of those 5 years; net income in 3.

Across Akebia Ther's full reported history, from 2014 to 2025, revenue grew from $ 700.23K to $ 236M and net income went from -$ 37M to -$ 5M. Revenue increased in 40% of the years measured; net income in 42%.

Akebia Ther currently holds a 5-year HDB Score of 5.2 out of 10. How the HDB Score is calculated.

Membership

Explore AKBA with current data

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 5,119 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year · Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies